^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan

    i
    Other names: CPT-11, CPT 11, DQ 2805, IHL-305, SN 38B11, U 101440E
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    11h
    Intensified Chemotherapy in CRC After Resection of Liver Metastases (clinicaltrials.gov)
    P2/3, N=124, Completed, Institut du Cancer de Montpellier - Val d'Aurelle | Phase classification: P3 --> P2/3
    Phase classification
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    15h
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
    17h
    Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. (PubMed, J Gastrointest Surg)
    Neoadjuvant SBRT achieves oncologic outcomes comparable to CFRT in BR/LA PC and is associated with greater adjuvant therapy use. A potential survival signal for SBRT in patients receiving FOLFIRINOX with CA19-9 > 1500U/mL is hypothesis-generating and warrants validation and formal interaction testing.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    20h
    CAPRI-3 GOIM: Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=480, Recruiting, University of Campania Luigi Vanvitelli
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    BRAF V600E • BRAF V600 • BRAF wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    HCB101-201: Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • carboplatin • 5-fluorouracil • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • Cyramza (ramucirumab) • oxaliplatin • etoposide IV • irinotecan • leucovorin calcium • HCB101
    1d
    IRIMAD: Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI (clinicaltrials.gov)
    P3, N=254, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Jun 2031 | Trial primary completion date: Sep 2027 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    1d
    RAGNAR: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (clinicaltrials.gov)
    P2, N=87, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Imdelltra (tarlatamab-dlle)
    1d
    Oridonin exerts dual therapeutic effects in MASLD mice by integrating lipid homeostasis and drug bioactivation via the LXRα-CES1/CES2 pathway. (PubMed, Acta Pharmacol Sin)
    LXRα knockout (LXRα-/-) mice exhibited aggravated HFD-induced steatosis and impaired metabolic conversion of the CES1/CES2 substrates, oseltamivir and irinotecan. Silencing of CES1 or CES2 abolished ORI's lipid-lowering effect, confirming their essential roles. These findings establish the LXRα-CES1/CES2 pathway as a pivotal node integrating hepatic lipid homeostasis and drug metabolism, positioning ORI as a promising therapeutic agent for MASLD.
    Preclinical • Journal
    |
    CES1 (Carboxylesterase 1)
    |
    irinotecan
    2d
    Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. (PubMed, Eur J Cancer)
    Patient- and tumour-specific characteristics strongly influence survival in mPAC patients receiving systemic therapy. These findings can support a more detailed risk stratification at diagnosis to optimise treatment selection, avoid both over- and undertreatment, and align care with individual patient expectations and values for more personalised treatment strategies.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    LDH elevation
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    2d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    3d
    ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov)
    P2, N=477, Suspended, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2027 --> Dec 2029 | Recruiting --> Suspended | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial suspension • Trial primary completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    RAS wild-type
    |
    Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Tukysa (tucatinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium
    3d
    JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan (clinicaltrials.gov)
    P3, N=123, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • anbenitamab repodatecan (JSKN003)